Education
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (TSE:HLS)
TSX:HLS
Total Valuation
HLS Therapeutics Inc has a market cap or net worth of C$139.89M. The enterprise value is C$195.41M.
Market CapC$139.89M
Enterprise ValueC$195.41M
Share Statistics
HLS Therapeutics Inc has 31,793,047 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,793,047
Owned by Insiders0.51%
Owned by Institutions1.57%
Financial Efficiency
HLS Therapeutics Inc’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee615.42K
Profits Per Employee-213.64K
Employee Count92
Asset Turnover0.35
Inventory Turnover0.99
Valuation Ratios
The current PE Ratio of HLS Therapeutics Inc is 0.00. HLS Therapeutics Inc’s PEG ratio is 0.00.
PE Ratio0.00
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.00
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.00
Income Statement
In the last 12 months, HLS Therapeutics Inc had revenue of 56.62M and earned -19.66M in profits. Earnings per share was -0.62.
Revenue56.62M
Gross Profit47.62M
Operating Income0.00
Pretax Income-15.58M
Net Income-19.66M
EBITDA17.22M
Earnings Per Share (EPS)-0.62
Cash Flow
In the last 12 months, operating cash flow was 8.00M and capital expenditures -15.00K, giving a free cash flow of 7.99M billion.
Operating Cash Flow8.00M
Free Cash Flow7.99M
Free Cash Flow per Share0.25
Dividends & Yields
HLS Therapeutics Inc pays an annual dividend of C$0.05, resulting in a dividend yield of ―
Dividend Per ShareC$0.05
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.54
52-Week Price Change-10.48%
50-Day Moving Average4.26
200-Day Moving Average3.76
Relative Strength Index (RSI)49.76
Average Volume (3m)13.80K
Important Dates
HLS Therapeutics Inc upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend DateApr 27, 2023
Financial Position
HLS Therapeutics Inc as a current ratio of 1.57, with Debt / Equity ratio of 93.14%
Current Ratio1.57
Quick Ratio1.17
Debt to Market Cap0.00
Net Debt to EBITDA2.85
Interest Coverage Ratio0.00
Taxes
In the past 12 months, HLS Therapeutics Inc has paid 4.07M in taxes.
Income Tax4.07M
Effective Tax Rate-0.26
Enterprise Valuation
HLS Therapeutics Inc EV to EBITDA ratio is 2.85, with an EV/FCF ratio of 6.13.
EV to Sales0.87
EV to EBITDA2.85
EV to Free Cash Flow6.13
EV to Operating Cash Flow6.12
Balance Sheet
HLS Therapeutics Inc has C$17.46M in cash and marketable securities with $66.45M in debt, giving a net cash position of C$48.99M billion.
Cash & Marketable SecuritiesC$17.46M
Total Debt$66.45M
Net CashC$48.99M
Net Cash Per ShareC$1.54
Tangible Book Value Per ShareC$0.00
Margins
Gross margin is 84.11%, with operating margin of 0.00%, and net profit margin of -34.71%.
Gross Margin84.11%
Operating Margin0.00%
Pretax Margin-27.52%
Net Profit Margin-34.71%
EBITDA Margin30.41%
EBIT Margin-9.71%
Analyst Forecast
The average price target for HLS Therapeutics Inc is C$5.92, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$5.92
Price Target Upside34.55% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-8.80%
EPS Growth Forecast26.77%